Toronto, Ontario — February 17, 2026 — Leads & Copy — DelphX Capital Markets Inc. (TSXV: DELX) (OTCQB: DPXCF) plans to seek approval from the TSX Venture Exchange to extend the exercise period of share purchase warrants.
The extension applies to 3,904,166 share purchase warrants, initially issued following a private placement announced on January 30, 2024. These warrants are exercisable at $0.20 per common share, and the company aims to extend their exercise period by one year, to January 30, 2027.
All other terms and conditions of the warrants will remain unchanged. The extension is subject to acceptance by the TSX Venture Exchange.
A total of 1,208,333 warrants are held by parties considered “related parties” of DelphX. Amending these warrants constitutes a “related party transaction” under Multilateral Instrument 61-101 and TSXV Policy 5.9. However, exemptions from formal valuation and minority approval requirements can be applied because the fair market value of the warrants does not exceed 25% of DelphX’s market capitalization.
DelphX Capital Markets Inc. focuses on developing and distributing structured products. Through its special purpose vehicle, Quantem LLC, the company allows broker-dealers to offer private placement securities that include both fixed-income and cryptocurrency-based solutions. DelphX’s securities include Collateralized Put Options (CPOs) and Collateralized Reference Notes (CRNs).
CPOs provide secured protection against rating downgrades of corporate bonds and losses in cryptocurrency holdings. CRNs allow investors to assume capped downgrade or cryptocurrency-loss exposure in exchange for returns.
All CPOs and CRNs are fully collateralized and held in custody by U.S. Bank. These instruments are proprietary products created and owned by DelphX Capital Markets Inc.
Source: DelphX Capital Markets Inc.
